Perfect Moment Ltd. (PMNT) Names CEO, CFO And Two New Directors

Perfect Moment Ltd. (PMNT) announced leadership changes effective November 15, 2026. Suzy Biszantz became CEO and director, Virginie Troudet was promoted to CFO, and Toby Maitland Hudson and Ben Pruess joined the board. Jane and Max Gottschalk stepped down from executive roles.

Original reporting
Published Nov 16, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Perfect Moment Ltd. (PMNT) Names CEO, CFO And Two New Directors — source image
Decision brief

The 30-second read

$PMNTNeutralLow
01

Why it matters

This is a governance and executive-structure update that can affect investor confidence and execution risk, but the provided text does not include performance data, guidance, or transaction terms.

02

Market read

Investors may reassess near-term execution and financial oversight following the CEO/CFO transition, but there is no new quantitative catalyst in the text.

03

What to watch

Traders may need to check the referenced June 11, 2026 8-K for prior context, and watch for subsequent filings that clarify strategy, cost structure, or reporting changes.

Relevance 5/10Novelty 5/10Timing: effective Nov. 15, 2026 leadership and board changes

Background

The article says the changes follow leadership updates disclosed in Perfect Moment Ltd.'s June 11, 2026 Form 8-K.

Company-level read

Ticker impact

$PMNTNeutralMedium confidence
Context

Perfect Moment Ltd. named Suzy Biszantz as CEO and director, promoted Virginie Troudet to CFO, and added two new directors effective Nov. 15, 2026.

Expected impact

Likely modest, two-sided reaction as traders price governance and execution risk without new earnings or guidance details.

Evidence & confidence

The disclosure is a corporate leadership/board refresh with no accompanying numbers, forecasts, or deal terms in the provided text.

Market effects

Limited sector read-through because the article contains no product, regulatory, or financial guidance changes.

No clear regional market linkage beyond company-specific governance sentiment.

No global macro or cross-border transaction details provided.

Counterpoint

Without any accompanying financial metrics, guidance, or strategic commitments, the market may treat this as routine board refresh rather than a catalyst.

Key entities

  • Perfect Moment Ltd.

    Subject of the article; announced CEO, CFO, and director changes effective Nov. 15, 2026.

  • Suzy Biszantz

    Became CEO and director effective Nov. 15, 2026.

  • Virginie Troudet

    Promoted to CFO effective Nov. 15, 2026.

  • Toby Maitland Hudson

    Joined the board effective Nov. 15, 2026.

  • Ben Pruess

    Joined the board effective Nov. 15, 2026.

Related articles

$PMNTMed

Perfect Moment Reports Fiscal Q1 2027 Results

Perfect Moment Ltd. (PMNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Perfect Moment Reports Fiscal Q1 2027 Results LONDON—August 17, 2026—Perfect Moment Ltd. (OTC: PMNT) (“Perfect Moment” or the “Company”), the high-performance, luxury lifestyle brand that fuses technical excellence with fashion-led designs, reported results for its f

$PMNTMed

Perfect Moment Reports Fiscal Q4 and Full Year 2026 Results

Perfect Moment Ltd. (PMNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Perfect Moment Reports Fiscal Q4 and Full Year 2026 Results Revenue increased double digits on a quarterly and annual basis Gross margin and adjusted EBITDA improved significantly for the fourth consecutive quarter driven by strategic ope

$NNVCMed

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

$UBERMed

Kohl’s products now available for delivery on Uber Eats

Uber (UBER) and Kohl's (KSS) partnered to offer Kohl's products via Uber Eats, covering 1,100+ U.S. stores. Items include apparel, home goods, and Sephora beauty products. The service launches before the holiday season, with a $10 discount on first orders over $50 until December 3, 2026. Kohl's operates 1,100+ stores in 49 states.